{"id":1231,"date":"2023-09-26T08:21:20","date_gmt":"2023-09-26T08:21:20","guid":{"rendered":"https:\/\/www.arcgroup.io\/west-london\/?p=1231"},"modified":"2023-09-26T08:21:55","modified_gmt":"2023-09-26T08:21:55","slug":"epsilogen-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/","title":{"rendered":"EPSILOGEN RESULTS PAVE THE WAY TO DEVELOPMENT OF NEW CLASS OF ANTI-CANCER DRUG"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/west-london\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_d3900205666dbe91a1a1b86a27df2b33\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp 1900w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen-300x95.webp 300w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen-1024x323.webp 1024w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen-768x243.webp 768w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen-1000x316.webp 1000w\" type=\"image\/webp\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">EPSILOGEN RESULTS PAVE THE WAY TO DEVELOPMENT OF NEW CLASS OF ANTI-CANCER DRUG<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/west-london\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<p><em><strong>After successful completion of first ever clinical trial of an IgE antibody<\/strong><\/em><\/p>\n\n\n\n<p>ARC West London member, <a href=\"https:\/\/epsilogen.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Epsilogen<\/a>, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, releases data from the first ever clinical trial of an IgE antibody.<\/p>\n\n\n\n<p>MOv18 IgE is Epsilogen\u2019s lead IgE antibody drug candidate and binds to anti-folate receptor (FR\u03b1), a well validated target for ovarian cancer. It was administered to 26 patients with high grade serous ovarian carcinoma whose cancer had become platinum-resistant.<\/p>\n\n\n\n<p>Results from the study published in <a href=\"https:\/\/www.nature.com\/articles\/s41467-023-39679-9\">Nature Communications<\/a> showed a manageable safety profile with transient urticaria being the most common adverse event. The urticaria always resolved within hours of dosing, either spontaneously or with the administration of systemic steroids and antihistamines.<\/p>\n\n\n\n<p>Although the trial was not designed to demonstrate efficacy, tumour shrinkage and an associated fall in CA 125 tumour marker level was seen in one patient. Notably, the authors of the paper observed that the anti-tumour activity \u201coccurred at doses very much lower than typically observed for IgG antibodies\u201d, reflecting fundamental differences in Fc-receptor affinity and effector cell biology.<\/p>\n\n\n\n<p><strong>Professor James Spicer, Professor of Experimental Cancer Medicine at King\u2019s College London, Consultant in Medical Oncology at Guy\u2019s and St Thomas\u2019 NHS Foundation Trust (GSTT) and the study\u2019s lead investigator, said<\/strong>: \u201c<em>IgE is a completely new form of antibody therapy which has shown great promise in this phase I trial. Our findings show that the drug was well tolerated in patients and shrunk a cancerous tumour in a patient with ovarian cancer. The results pave the way to development of an entirely new class of anti-cancer drug for people with chemotherapy-resistant cancers. The immunology expertise in King\u2019s College London laboratories allowed us to undertake this trial of a completely new form of antibody therapy<\/em>.\u201d<\/p>\n\n\n\n<p><strong>Dr Tim Wilson, Chief Executive Officer of Epsilogen, commented:<\/strong>&nbsp;\u201c<em>The data published in Nature Communications, are encouraging and add further validation to support our belief that IgE antibodies have the potential to emerge as an entirely new treatment modality for patients with cancer. We have a robust clinical development plan in place to progress MOv18 IgE further into the clinic and the data generated will assist us in the development of our other IgE antibody drug candidates<\/em>\u201d.<\/p>\n\n\n\n<p><em>Image credit: Epsilogen<\/em><\/p>\n\n\n    <section class=\"news-archive \" id=\"block_1620efa6ad537972b8e2ee49fea86494\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/west-london\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/west-london\/blog\/2026\/03\/26\/arc-west-london-and-imperial-incubator-announce-leap-lab-pass-winners-at-newly-opened-leap-incubator-lab\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2026\/03\/WhatsApp-Image-2026-03-10-at-10.24.08-2.jpeg 2048w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2026\/03\/WhatsApp-Image-2026-03-10-at-10.24.08-2-300x225.jpeg 300w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2026\/03\/WhatsApp-Image-2026-03-10-at-10.24.08-2-1024x768.jpeg 1024w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2026\/03\/WhatsApp-Image-2026-03-10-at-10.24.08-2-768x576.jpeg 768w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2026\/03\/WhatsApp-Image-2026-03-10-at-10.24.08-2-1000x750.jpeg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2026\/03\/WhatsApp-Image-2026-03-10-at-10.24.08-2.jpeg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/west-london\/blog\/2026\/03\/26\/arc-west-london-and-imperial-incubator-announce-leap-lab-pass-winners-at-newly-opened-leap-incubator-lab\/\" target=\"_self\">\n\t\t\t\tARC WEST LONDON AND IMPERIAL INCUBATOR ANNOUNCE LEAP LAB PASS WINNERS AT NEWLY OPENED LEAP INCUBATOR LAB\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/west-london\/blog\/2025\/12\/05\/imperials-leap-incubator-attracts-five-start-ups\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2022\/09\/Motherlab-Copy-01160-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2022\/09\/Motherlab-Copy-01160-300x158.jpg 300w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2022\/09\/Motherlab-Copy-01160-1024x540.jpg 1024w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2022\/09\/Motherlab-Copy-01160-768x405.jpg 768w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2022\/09\/Motherlab-Copy-01160-1000x527.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2022\/09\/Motherlab-Copy-01160-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/west-london\/blog\/2025\/12\/05\/imperials-leap-incubator-attracts-five-start-ups\/\" target=\"_self\">\n\t\t\t\tImperial&#8217;s Leap Incubator attracts five innovative start-ups in first month\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/west-london\/blog\/2025\/12\/02\/delivering-the-uks-life-sciences-sector-plan\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/12\/1763038888374.jpg 2048w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/12\/1763038888374-300x225.jpg 300w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/12\/1763038888374-1024x768.jpg 1024w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/12\/1763038888374-768x576.jpg 768w, https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/12\/1763038888374-1000x750.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/12\/1763038888374.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-purple\">Uncategorized<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/west-london\/blog\/2025\/12\/02\/delivering-the-uks-life-sciences-sector-plan\/\" target=\"_self\">\n\t\t\t\tDelivering the UK\u2019s Life Sciences Sector Plan: A connected ecosystem in action at ARC West London\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>After successful completion of first ever clinical trial of an IgE antibody ARC West London member, Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, releases data from the first ever clinical trial of an IgE antibody. MOv18 IgE is Epsilogen\u2019s lead IgE antibody drug candidate and binds to [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":1232,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22],"tags":[6216],"class_list":["post-1231","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-life-science-and-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ARC | Epsilogen announce completion of clinical trial<\/title>\n<meta name=\"description\" content=\"Epsilogen, a leader in the development of immunoglobulin E antibodies to treat cancer, announce the final phase I data from the first clinical trial of an IgE antibody therapeutic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARC | Epsilogen announce completion of clinical trial\" \/>\n<meta property=\"og:description\" content=\"Epsilogen, a leader in the development of immunoglobulin E antibodies to treat cancer, announce the final phase I data from the first clinical trial of an IgE antibody therapeutic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC West London\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-26T08:21:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-26T08:21:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1900\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"liamjoyce\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"liamjoyce\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/\"},\"author\":{\"name\":\"liamjoyce\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04\"},\"headline\":\"EPSILOGEN RESULTS PAVE THE WAY TO DEVELOPMENT OF NEW CLASS OF ANTI-CANCER DRUG\",\"datePublished\":\"2023-09-26T08:21:20+00:00\",\"dateModified\":\"2023-09-26T08:21:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/\"},\"wordCount\":393,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp\",\"keywords\":[\"Life science and Health\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/\",\"url\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/\",\"name\":\"ARC | Epsilogen announce completion of clinical trial\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp\",\"datePublished\":\"2023-09-26T08:21:20+00:00\",\"dateModified\":\"2023-09-26T08:21:55+00:00\",\"description\":\"Epsilogen, a leader in the development of immunoglobulin E antibodies to treat cancer, announce the final phase I data from the first clinical trial of an IgE antibody therapeutic.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp\",\"width\":1900,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/west-london\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EPSILOGEN RESULTS PAVE THE WAY TO DEVELOPMENT OF NEW CLASS OF ANTI-CANCER DRUG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/west-london\/\",\"name\":\"ARC West London\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#organization\"},\"alternateName\":\"ARC West London\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/west-london\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#organization\",\"name\":\"ARC West London\",\"alternateName\":\"ARC West London\",\"url\":\"https:\/\/www.arcgroup.io\/west-london\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/06\/cropped-ARC-SUBBRANDS-LOGOS-02-WEST-LONDON-3.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/06\/cropped-ARC-SUBBRANDS-LOGOS-02-WEST-LONDON-3.png\",\"width\":512,\"height\":512,\"caption\":\"ARC West London\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04\",\"name\":\"liamjoyce\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g\",\"caption\":\"liamjoyce\"},\"url\":\"https:\/\/www.arcgroup.io\/west-london\/blog\/author\/liamjoyce\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ARC | Epsilogen announce completion of clinical trial","description":"Epsilogen, a leader in the development of immunoglobulin E antibodies to treat cancer, announce the final phase I data from the first clinical trial of an IgE antibody therapeutic.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"ARC | Epsilogen announce completion of clinical trial","og_description":"Epsilogen, a leader in the development of immunoglobulin E antibodies to treat cancer, announce the final phase I data from the first clinical trial of an IgE antibody therapeutic.","og_url":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/","og_site_name":"ARC West London","article_published_time":"2023-09-26T08:21:20+00:00","article_modified_time":"2023-09-26T08:21:55+00:00","og_image":[{"width":1900,"height":600,"url":"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp","type":"image\/webp"}],"author":"liamjoyce","twitter_card":"summary_large_image","twitter_misc":{"Written by":"liamjoyce","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/"},"author":{"name":"liamjoyce","@id":"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04"},"headline":"EPSILOGEN RESULTS PAVE THE WAY TO DEVELOPMENT OF NEW CLASS OF ANTI-CANCER DRUG","datePublished":"2023-09-26T08:21:20+00:00","dateModified":"2023-09-26T08:21:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/"},"wordCount":393,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/west-london\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp","keywords":["Life science and Health"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/","url":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/","name":"ARC | Epsilogen announce completion of clinical trial","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/west-london\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp","datePublished":"2023-09-26T08:21:20+00:00","dateModified":"2023-09-26T08:21:55+00:00","description":"Epsilogen, a leader in the development of immunoglobulin E antibodies to treat cancer, announce the final phase I data from the first clinical trial of an IgE antibody therapeutic.","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#primaryimage","url":"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp","contentUrl":"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2023\/09\/epsiologen.webp","width":1900,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/west-london\/blog\/2023\/09\/26\/epsilogen-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/west-london\/"},{"@type":"ListItem","position":2,"name":"EPSILOGEN RESULTS PAVE THE WAY TO DEVELOPMENT OF NEW CLASS OF ANTI-CANCER DRUG"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/west-london\/#website","url":"https:\/\/www.arcgroup.io\/west-london\/","name":"ARC West London","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/west-london\/#organization"},"alternateName":"ARC West London","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/west-london\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/west-london\/#organization","name":"ARC West London","alternateName":"ARC West London","url":"https:\/\/www.arcgroup.io\/west-london\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/06\/cropped-ARC-SUBBRANDS-LOGOS-02-WEST-LONDON-3.png","contentUrl":"https:\/\/www.arcgroup.io\/west-london\/wp-content\/uploads\/sites\/5\/2025\/06\/cropped-ARC-SUBBRANDS-LOGOS-02-WEST-LONDON-3.png","width":512,"height":512,"caption":"ARC West London"},"image":{"@id":"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04","name":"liamjoyce","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/west-london\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g","caption":"liamjoyce"},"url":"https:\/\/www.arcgroup.io\/west-london\/blog\/author\/liamjoyce\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/posts\/1231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/comments?post=1231"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/posts\/1231\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/media\/1232"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/media?parent=1231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/categories?post=1231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/west-london\/wp-json\/wp\/v2\/tags?post=1231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}